



Federal Retail Pharmacy Program Updates

Federal Retail Pharmacy Partnership for COVID-19 website

Find up to date information and newsletters on our [website](#) for the Federal Retail Pharmacy Partnership for COVID-19.

[Sitio web en Español](#) para participantes del programa de vacunas COVID

Important updates for both programs

New quarterly attestations process starting October 1

In our efforts to streamline the quarterly attestation process, both the vaccine and therapeutics quarterly attestations will now be sent in the same week to participants in both programs. Participants in the vaccine program only will only receive the vaccine attestation, but participants in both programs will receive both attestations so they can sign them and return them both in the same week. This new process will begin in the first week of October, and will continue in January, April, and July. Both attestations will be sent to the primary contact listed in the applicable program and you will have a 14-day window to complete and return the forms.

Vaccine program updates

Update on availability of Moderna bivalent vaccines

Moderna bivalent vaccine backorder status

Due to supply constraints, we have been unable to completely fulfill requests for allocation of the COVID-19 Moderna bivalent vaccine. We were able to ship 100 doses to most pharmacies that had requested allocation. If you have not received any doses yet, we will ship at least 100 doses as soon as we receive additional allocation of the Moderna bivalent. If you requested more than 100 doses, we will automatically fulfill the remaining number of doses you requested once we receive additional product. You do not need to place an additional request through AmerisourceBergen. Please note that it may be several weeks before we receive enough product to fulfill your remaining requested quantity of doses.

Future Moderna bivalent vaccine allocation requests

As soon as we have been able to fulfill all backorders and are ensured there is an adequate steady supply of the Moderna bivalent vaccine available, we will once again place Moderna bivalent vaccine on the ABC Order COVID portal for allocation requests.

We continue to be in close contact with the CDC regarding the status of future inventory of the Moderna bivalent vaccine, and we will keep you updated via our weekly COVID-19 Federal Retail Pharmacy Partnership newsletters.

HHS encourages all providers to use and order the Pfizer bivalent doses as much as possible as we await additional Moderna bivalent supply.

We do have adequate supply of the Pfizer bivalent available for ordering in the ABC Order COVID portal. The Pfizer bivalent boosters are approved for administration to ages 12 and older.

Pediatric bivalent booster update

If authorized by FDA, CDC anticipates a recommendation for bivalent COVID-19 vaccine as a booster for pediatric age groups in early to mid-October. Bivalent products expected to be under consideration include the bivalent Pfizer-BioNTech vaccine for children aged 5-11 years and bivalent Moderna vaccine in children aged 6-17 years, for those individuals who have already received their primary vaccine series.

It is expected that if bivalent boosters are authorized for individuals aged 5 years and older as a booster, monovalent mRNA COVID-19 vaccines may no longer be authorized as booster doses. Providers should review any FDA and CDC guidance for bivalent vaccine in children aged 5 years and older, since bivalent vaccines may be the only authorized and recommended COVID-19 boosters for this age group. At this time, it is expected that monovalent vaccines will remain appropriate for primary series for this age group. Please take into account the potential authorization of the bivalent booster as you are scheduling boosters for children in October.

Novavax update

Novavax should still be ordered by emailing the request with your NCPDP number to the COVID email box at COVIDVaccines@AmerisourceBergen.com.

- [Updated Clinical Considerations](#)

Oral therapeutics program updates

The Administration for Strategic Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) announced the authorization of an extension to the shelf life from 12 months to 18 months for certain lots of the Pfizer antiviral therapy, Paxlovid (nirmatrelvir tablets and ritonavir tablets co-packaged for oral use), which is currently authorized for emergency use for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients (12 years of age and older weighing at least 40kg).

As a result of this extension, lots of Paxlovid with dates of expiry from July 2022 to May 2023 may be stored for an additional six months from the labeled date of expiry. As required by the emergency use authorization, unopened cartons of Paxlovid (300 mg nirmatrelvir and 100 mg ritonavir, or 150 mg nirmatrelvir and 100 mg ritonavir), must be appropriately held in accordance with storage conditions detailed in the authorized [Fact Sheet for Health Care Providers](#). FDA granted this extension following a thorough review of data submitted by Pfizer.

[Extended Expiry Dating for Paxlovid Authorized under EUA 105](#)

Please contact COVID19Therapeutics@hhs.gov with any questions and visit the [ASPR website](#) for additional information regarding Paxlovid.

Resources

Updated Implementation and Allocation Guides

- [Therapeutics Allocation guide](#)

- [Therapeutics implementation guide](#)
- [Vaccine implementation guide](#)
- [Vaccine allocation guide](#)

COVID-19 Bivalent Booster Marketing Materials

Let your patients know that you have the latest booster shot available at your pharmacy with new print and digital marketing materials. Visit the “COVID-19 Vaccine” library in [Brand Central Station](#) and [SOCj](#) to access the materials.



Surveys, reporting, reminders

Are you interested in dispensing COVID-19 antiviral therapies?

If you are currently enrolled in the vaccine program and are interested in participating in the antiviral program, please email the Elevate Enrollments team at elevateenrollments@amerisourcebergen.com.

At this time, only pharmacies enrolled in the vaccine program may participate in the antiviral program.

Questions? Continue to work with your Business Coach or Sales Executive or send questions to COVIDVaccines@AmerisourceBergen.com. Please include your pharmacy name and NCPDP on all communications. This information will help us expedite our response to you.

AmerisourceBergen

